BG Medicine (BG Medicine) Debt-to-Asset : 0.00 (As of Dec. 2015)

View and export this data going back to 2011. Start your Free Trial

What is BG Medicine Debt-to-Asset?

BG Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2015 was $0.00 Mil. BG Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2015 was $0.00 Mil. BG Medicine's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2015 was $2.13 Mil. BG Medicine's debt to asset for the quarter that ended in Dec. 2015 was 0.00.

BG Medicine Debt-to-Asset Historical Data

The historical data trend for BG Medicine's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BG Medicine Debt-to-Asset Chart

BG Medicine Annual Data

Trend

Dec05

Dec06

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Debt-to-Asset

Get a 7-Day Free Trial

0.65

0.78

0.57

BG Medicine Quarterly Data
	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15
Debt-to-Asset	Get a 7-Day Free Trial															0.57	0.72	1.23	-	-

Competitive Comparison of BG Medicine's Debt-to-Asset

For the Medical Instruments & Supplies subindustry, BG Medicine's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BG Medicine's Debt-to-Asset Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, BG Medicine's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where BG Medicine's Debt-to-Asset falls into.

BG Medicine Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

BG Medicine's Debt-to-Asset for the fiscal year that ended in Dec. 2015 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	2.133
	=	0.00

BG Medicine's Debt-to-Asset for the quarter that ended in Dec. 2015 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(0	+	0)	/	2.133
	=	0.00

BG Medicine (OTCPK:BGMD) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

BG Medicine Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of BG Medicine's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

BG Medicine (BG Medicine) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » BG Medicine Inc (OTCPK:BGMD) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

N/A

Address

303 Wyman Street, Suite 300, Waltham, MA, USA, 02451

Website

http://www.bg-medicine.com

BG Medicine Inc manufacture and sell diagnostic products that are used to guide the patients suffering from heart failure and related disorders in the United States. It distributes its products such as BGM Galectin-3 Test, an in vitro diagnostic device that measures galectin-3 in serum or plasma by enzyme-linked immunosorbent assay on a microtiter plate platform; and CardioSCORE Test, a multi-analyte biomarker-based blood test used for the assessment of near-term risk of atherothrombotic cardiovascular events, such as heart attack and ischemic stroke.

Executives

Jeffrey R Luber	director	100 CAMPUS DRIVE, C/O EXACT SCIENCES CORP, MARLBOROUGH MA 01752
Noubar Afeyan	director, 10 percent owner	C/O FLAGSHIP PIONEERING, INC., 55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Stelios Papadopoulos	director	3 SOMERSET DRIVE SOUTH, GREAT NECK NY 11020
Harry W Wilcox	director	ONE KENDALL SQ, BLDG 700, CAMBRIDGE MA 02139
Agtc Partners, L.p.	10 percent owner	C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Newcogen Group, Inc.	10 percent owner	C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Applied Genomic Technology Capital Fund Lp	10 percent owner	C/O FLAGSHIP VENTURES ONE MEMORIAL DRIVE, 7TH FLOOR CAMBRIDGE MA 02142
Flagship Pioneering Inc.	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Agtc Advisors Fund Lp	10 percent owner	ONE MEMORIAL DRIVE 7TH FLOOR CAMBRIDGE MA 02142
Kania Edwin M Jr	10 percent owner
Flagship Ventures Fund 2007, L.p.	10 percent owner	55 CAMBRIDGE PARKWAY, 8TH FLOOR, CAMBRIDGE MA 02142
Flagship Ventures 2007 General Partner Llc	10 percent owner	55 CAMBRIDGE PARKWAY, SUITE 800E, CAMBRIDGE MA 02142
Brian S Posner	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142
Stephane Bancel	director	320 BENT STREET, CAMBRIDGE MA 02141
Harris Timothy J.r.	director	C/O BG MEDICINE, 610 LINCOLN STREET NORTH, WALTHAM MA 02451

BG Medicine (BG Medicine) Headlines

No Headlines